Centocor: Ustekinumab Works in Psoriasis After One Year
This article was originally published in The Pink Sheet Daily
Executive Summary
Second Phase III pivotal study backs fewer-dose benefit
You may also be interested in...
FDA Notes Theoretical Cancer Risk For Centocor’s Ustekinumab
MAb for psoriasis has favorable odds for a June 17 recommendation by advisory panel, analysts say.
FDA Notes Theoretical Cancer Risk For Centocor’s Ustekinumab
MAb for psoriasis has favorable odds for a June 17 recommendation by advisory panel, analysts say.
J&J Combines Ortho Biotech, Centocor
At least 400 jobs lost to fallout from anemia-drug troubles.